Patents by Inventor Cecile Gouttefangeas

Cecile Gouttefangeas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Powerful MHC-class II peptides derived from survivin
    Patent number: 11957729
    Abstract: The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: April 16, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Hans Georg Rammensee, Stefan Stevanovic, Cecile Gouttefangeas, Toni Weinschenk, Peter Lewandrowski
  • NOVEL AND POWERFUL MHC-CLASS II PEPTIDES DERIVED FROM SURVIVIN
    Publication number: 20200078439
    Abstract: The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: July 12, 2019
    Publication date: March 12, 2020
    Inventors: Hans Georg RAMMENSEE, Stefan STEVANOVIC, Cecile GOUTTEFANGEAS, Toni WEINSCHENK, Peter LEWANDROWSKI
  • Powerful MHC-class II peptides derived from survivin
    Patent number: 10434136
    Abstract: The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: October 8, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Hans-Georg Rammensee, Stefan Stevanovic, Cecile Gouttefangeas, Toni Weinschenk, Peter Lewandrowski
  • HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
    Patent number: 9023804
    Abstract: Methods and compositions for immunotherapeutic treatment of prostate cancer are disclosed. More specifically methods of treating patients with prostate cancer comprising administering compositions comprising HLA-binding peptides derived from prostate-associated antigenic molecules, either with or without immunological adjuvants, are disclosed.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: May 5, 2015
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Toni Weinschenk, Peter Lewandrowski, Hans Georg Rammensee, Stefan Stevanovic, Cecile Gouttefangeas
  • HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
    Patent number: 9023802
    Abstract: Methods and compositions for immunotherapeutic treatment of prostate cancer are disclosed. Patients are treated with compositions comprising HLA-binding peptides derived from prostate-associated antigenic molecules, either with or without immunological adjuvants.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: May 5, 2015
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Hans Georg Rammensee, Stefan Stevanovic, Cecile Gouttefangeas, Toni Weinschenk, Peter Lewandrowski
  • HLA-BINDING PEPTIDES DERIVED FROM PROSTATE-ASSOCIATED ANTIGENIC MOLECULES AND METHODS OF USE THEREOF
    Publication number: 20130336922
    Abstract: Methods and compositions for immunotherapeutic treatment of prostate cancer are disclosed. More specifically methods of treating patients with prostate cancer comprising administering compositions comprising HLA-binding peptides derived from prostate-associated antigenic molecules, either with or without immunological adjuvants, are disclosed.
    Type: Application
    Filed: November 14, 2011
    Publication date: December 19, 2013
    Applicant: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Peter Lewandrowski, Hans Georg Rammensee, Stefan Stevanovic, Cecile Gouttefangeas
  • HLA-BINDING PEPTIDES DERIVED FROM PROSTATE-ASSOCIATED ANTIGENIC MOLECULES AND METHODS OF USE THEREOF
    Publication number: 20120082691
    Abstract: Methods and compositions for immunotherapeutic treatment of prostate cancer are disclosed. Patients are treated with compositions comprising HLA-binding peptides derived from prostate-associated antigenic molecules, either with or without immunological adjuvants.
    Type: Application
    Filed: December 14, 2010
    Publication date: April 5, 2012
    Applicant: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Hans Georg Rammensee, Stefan Stevanovic, Cecile Gouttefangeas, Toni Weinschenk, Peter Lewandrowski